Evidence map›Paper›PMID 37232822›Full record

ArticleCurrent oncology (Toronto, Ont.)2023

Pregnancy in a Young Patient with Metastatic HER2-Positive Breast Cancer-Between Fear of Recurrence and Desire to Procreate.

Cristina Marinela Oprean, Andrei Dorin Ciocoiu, Nusa Alina Segarceanu, Diana Moldoveanu, Alexandra Stan, Teodora Hoinoiu, Ioana Chiorean-Cojocaru, Daciana Grujic, Adelina Stefanut, Daniel Pit and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Current oncology (Toronto, Ont.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Sex and age disparities in goserelin safety: a global pharmacovigilance study.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  3. Review
  4. Management and treatment of breast cancer in pregnant women.Archives of medical science : AMS · 2026
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Cristina Marinela OpreanANAPATMOL Research Center, 'Victor Babes' University of Medicine and Pharmacy of Timisoara, 300041 Timisoara, Romania.ORCID 0000-0001-5000-5422
Andrei Dorin CiocoiuDepartment of Oncology, ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania.
Nusa Alina SegarceanuDepartment of Oncology, ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania.
Diana MoldoveanuDepartment of Oncology, ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania.
Alexandra StanDepartment of Oncology, City Clinical Emergency Hospital of Timisoara, Victor Babes Blvd. No. 22, 300595 Timisoara, Romania.
Teodora HoinoiuDepartment of Clinical Practical Skills, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Sq. Nr. 2, 300041 Timisoara, Romania.ORCID 0000-0001-7753-7621
Ioana Chiorean-CojocaruDepartment of Obstetrics and Gynaecology, Faculty of Medicine and Pharmacy, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Daciana GrujicDepartment of Plastic and Reconstructive Surgery, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Sq. Nr. 2, 300041 Timisoara, Romania.
Adelina StefanutDepartment of Psichology & Sociology, West University, Timisora, Blvd. No. 4, Vasile Pârvan, 300223 Timisoara, Romania.
Daniel PitCenter for Advanced Research in Cardiovascular Pathology and Hemostaseology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Alis DemaANAPATMOL Research Center, 'Victor Babes' University of Medicine and Pharmacy of Timisoara, 300041 Timisoara, Romania.
Victor Babeș University of Medicine and Pharmacy Timișoara · ROWest University of Timişoara · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most frequent neoplasm among women and the second leading cause of death by cancer. It is the most frequent cancer diagnosed during pregnancy. Pregnancy-associated breast cancer is defined as breast cancer that is diagnosed during pregnancy and/or in the postpartum period. Data about young women with metastatic HER2-positive cancer who desire a pregnancy are scarce. The medical attitude in these clinical situations is difficult and nonstandardized. We present the case of a 31-year-old premenopausal woman diagnosed in December 2016 with a stage IV Luminal HER2-positive metastatic breast cancer (pT2 N0 M1 hep). The patient was initially treated by surgery in a conservative manner. Postoperatively, the presence of liver metastases was found by CT investigation. Consequently, line I treatment (docetaxel l75 mg/m² iv; trastuzumab 600 mg/5 mL sq) and ovarian drug suppression (Goserelin 3.6 mg sq at 28 days) was administered. After nine cycles of treatment, the patient's liver metastases had a partial response to the therapy. Despite having a favorable disease evolution and a strong desire to procreate, the patient vehemently refused to continue any oncological treatment. The psychiatric consult highlighted an anxious and depressive reaction for which individual and couple psychotherapy sessions were recommended. After 10 months from the interruption of the oncological treatment, the patient appeared with an evolving pregnancy of 15 weeks. An abdominal ultrasound revealed the presence of multiple liver metastases. Knowing all the possible effects, the patient consciously decided to postpone the proposed second-line treatment. In August 2018, the patient was admitted in the emergency department with malaise, diffuse abdominal pain and hepatic failure. Abdominal ultrasound found a 21-week-old pregnancy which had stopped in evolution, multiple liver metastases and ascites in large quantity. She was transferred to the ICU department where she perished just a few hours later. Conclusions/Discussion: From a psychological standpoint, the patient had an emotional hardship to make the transition from the status of a healthy person to the status of a sick person. Consequently, she entered a process of emotional protection of the positive cognitive distortion type, which favored the decision to abandon treatment and try to complete the pregnancy to the detriment of her own survival. The patient delayed the initiation of oncological treatment in pregnancy until it was too late. The consequence of this delay in treatment led to the death of the mother and fetus. A multidisciplinary team worked to provide this patient with the best medical care and psychological assistance throughout the course of the disease.

Indexed as

Breast NeoplasmsLiver NeoplasmsAdultErb-b2 Receptor Tyrosine KinasesFearFemaleHumansPregnancyTrastuzumabErb-b2 Receptor Tyrosine KinasesTrastuzumabchemotherapymetastatic breast cancerPABCpregnancypregnancy-associated breast cancertrastuzumab

Identifiers

PMID37232822
PMCPMC10217573
OpenAlexW4375862403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.